Literature DB >> 7083202

Aromatase in human breast carcinoma.

E Perel, M E Blackstein, D W Killinger.   

Abstract

Breast carcinoma tissue is capable of forming estrogens from circulating androgen precursors. In this study, aromatase was examined in homogenates of breast adipose and breast carcinoma tissue, in normal and abnormal parenchymal breast tissue, and in breast carcinoma cells in culture. Homogenates of carcinoma tissue showed a wide range of activity in the conversion of adrostenedione to estrone. The mean conversion in carcinoma tissue was greater than that seen in parenchymal tissue from patients with gynecomastia and mammary dysplasia. Homogenates of breast adipose tissue from patients with benign and malignant disorders showed comparable aromatase activity. Three cell lines isolated from a primary breast carcinoma differed in their aromatase activity demonstrating a heterogeneity of aromatase activity in cells from a single tumor. Studies of aromatase activity in breast carcinoma cells in culture over a period of 8 hr demonstrated progressive estrone formation. Testosterone formation from androstenedione was noted in all studies using both homogenates and cell cultures. Testosterone formation from androstenedione was approximately 10-fold greater than was the formation of estrone from androstenedione in all studies. The metabolism of androstenedione to other androgens examined in homogenates of normal and carcinomatous breast tissue revealed that the major products were androsterone, 5 beta-androsterone, dihydrotestosterone, and epiandrosterone. Both estrogen and androgen formation within the cell may be important in determining the cellular response.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7083202

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Estrogen metabolism as a regulator of estrogen action in the mammary gland.

Authors:  M Miettinen; V Isomaa; H Peltoketo; D Ghosh; P Vihko
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

2.  In vivo influence of androgens on the cell kinetics and chromatin pattern of the MXT mouse mammary tumor treated or not by aminoglutethimide.

Authors:  Y de Launoit; R Kiss
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

Review 3.  Aromatase inhibitors and inactivators for breast cancer therapy.

Authors:  Per E Lønning
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 4.  Could aminoglutethimide replace adrenalectomy?

Authors:  A L Harris
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

Review 5.  Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.

Authors:  V C Njar; A M Brodie
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 6.  The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.

Authors:  Angela Brodie; Vincent Njar; Luciana Furtado Macedo; T Sean Vasaitis; Gauri Sabnis
Journal:  Urol Oncol       Date:  2009 Jan-Feb       Impact factor: 3.498

7.  Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.

Authors:  Naoki Kanomata; Shiro Matsuura; Tsunehisa Nomura; Junichi Kurebayashi; Taisuke Mori; Jo Kitawaki; Takuya Moriya
Journal:  PLoS One       Date:  2017-05-10       Impact factor: 3.240

8.  Hormonal Homologies between Canine Mammary Cancer and Human Breast Cancer in a Series of Cases.

Authors:  Paloma Jimena de Andrés; Sara Cáceres; Juan Carlos Illera; Belén Crespo; Gema Silván; Felisbina Luisa Queiroga; Maria José Illera; Maria Dolores Pérez-Alenza; Laura Peña
Journal:  Vet Sci       Date:  2022-07-29

9.  Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells.

Authors:  V M Macaulay; J E Nicholls; J Gledhill; M G Rowlands; M Dowsett; A Ashworth
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.